|
SMi presents its 2nd annual Biobanking event.
Access to samples is paramount to scientific research. DNA, RNA, proteins, cells and tissues of all types are being stored centrally for later use in experiments conducted by academia and industry alike. This has given rise to the concept of Biobanking, which in 2009 was described by Time Magazine as one of the ’10 Ideas Changing the World Right Now’.
Although not an entirely new conception, there is significant change driving current development. With greater impetus being put on data sharing, interoperability and harmonisation of biobanks, single centre research facilities are evolving into research infrastructures. Considering that sharing, storing and using biosamples can vary wildly in cost, social and scientific impact there are efforts now being made to associate value to existing biological resources.
SMi’s Biobanking event will aim to address important issues experienced by those who donate, manage and expend biobank samples. Key opinion leaders will provide up to date information on the important topics of today, and there will be opportunities for discussion and networking across a range of professions.
 Comments from last year’s delegates included:
‘Well planned, great venue, good range of attendees’
‘Very Informative; I wish I had attended years ago’
Why should you attend this event?
- Determine the significance of the Bio Resource Impact Factor (BRIF)
|
- Examine quality control and quality assurance practices
|
- Discover how biobanks are used in drug discovery
|
- Explore technologies for managing biobanks
|
- Find out why room temperature storage is better than cryogenics
|
- Communicate between academia and industry over access to samples
|
- Discuss obstacles to people donating tissue for biomedical research
|
- Reveal challenges facing new biobanks and building sustainability
|
Hear keynote addresses from:
Helen Moore, Director of Biospecimen Research Network (BRN), Office of Biorepositories and Biospecimen Research (OBBR), National Cancer Institute
Julie Corfield, Director, Areteva Ltd.
Our expert speaker line-up also includes:
|
Pablo Arrisi, Senior Biosample Operations Manager, Roche
|
George Tokiwa, Associate Scientific Director and Specimen Inventory Management Lead, Merck
|
| Kristian Hveem, Head of Hunt Biobank, Leader Biobank Norway, Norwegian University of Science and Technology (NTNU) |
Geraldine Thomas, Chair in Molecular Pathology, Chernobyl Tissue Bank
|
Anthony Rowe, Principal Research Scientist, External Innovation R&D IT, Janssen
|
Martin Yuille, Joint Director, Centre for Integrated Genomic Medical Research, University of Manchester
|
Mads Almose Røpke, Senior Scientist, LEO Pharma
|
Ma’n H. Zawati, Academic Associate, Centre of Genomics and Policy, McGill University
|
John Cason, Director of the Infectious Diseases BioBank, King’s College London
|
Kirstin Goldring, Biobank Facilitator, UCL Biobank
|
| Brian Thomson, Director of Research and Innovation, Nottingham University Hospitals |
Paul Hofman, Head of Human Biobank Unit, Pasteur Hospital
|
Katherine Littler, Policy Adviser, Strategic Planning and Policy Unit, Wellcome Trust
|
Raymond Dalgleish, Department of Genetics, University of Leicester
|
Brian Kelly, Regulatory Lawyer, Covington & Burling LLP
|
Celine Lewis, Public Engagement Lead STRATUM , Genetic Alliance
|
Amir Gander, Senior Knowledge Transfer Associate, UCL
|
Martyn Foster, Independent Consultant in Experimental Pathology
|
Neil Formstone, Patient & Public Representative
Peter Jackson, Managing Director, Elpro UK
|
Who should attend?
 Heads of Department, Directors, Managers, Team Leaders Researchers and Scientists from:
Research and Development
Supply Chain
Translational science
Population based biobanks
Disease based biobanks
Hospital Trusts
Research Institutes
Sample Managers
Tecnology Transfer
Bioinnovation
|
Events Home Page
